author-photo

Diana M. Brainard

Ragon Institute of MGH, MIT and Harvard

343

Papers

13129

Citations

Citation Trend

Filter By

Papers (343) Sort By

Journal Conference Others

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.

2021 The Lancet Gastroenterology & Hepatology
Show All
- Source
- Cite
- Save
Citations (9)
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

2021 Intensive Care Medicine
Show All
- Source
- Cite
- Save
Citations (3)
P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION

2021 Annals of Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial

2021 The Lancet Child & Adolescent Health
Show All
- Source
- Cite
- Save
Citations (0)
Compassionate Use of Remdesivir in Children With Severe COVID-19.

2021 Pediatrics
Show All
- Source
- Cite
- Save
Citations (11)
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.

2021 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (2)
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.

2021 Journal of Antimicrobial Chemotherapy
Show All
- Source
- Cite
- Save
Citations (1)
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)

2021 Gut
Show All
- Source
- Cite
- Save
Citations (0)
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

2021 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (4)